The Utility of Non-Invasive Liquid Biopsy for Mutational Analysis and Minimal Residual Disease Assessment in Extramedullary Multiple Myeloma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16440
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Minimal Residual Disease Assessment in Multiple Myeloma: Utility and Feasibility in Resource Constraint Settings of India

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Minimal Residual Disease Testing After Stem Cell Transplantation for Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2015English

Flow Cytometry in the Diagnosis and Monitoring of Minimal Residual Disease in Multiple Myeloma

Oncogematologiya
OncologyHematology
2017English

Prospective Molecular Monitoring of Minimal Residual Disease After Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology
Hematology
2018English

Prospective Trial of Minimal Residual Disease Assessment by Multiparametric Flow Cytometry for Multiple Myeloma in the Era of Bortezomib-Based Chemotherapy

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Liquid Biopsy for Minimal Residual Disease Detection in Leukemia Using a Portable Blast Cell Biochip

npj Precision Oncology
2019English

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy